HTG Molecular Diagnostics Inc (HTGMQ)
0.0025
0.00 (0.00%)
USD |
OTCM |
May 14, 10:44
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 0.0055M |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -99.94% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | -- |
| Price to Book Value | -- |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | -- |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 100.00% |
Profile
| HTG Molecular Diagnostics Inc is a commercial-stage RNA platform-based life sciences company focused on advancing the promise of precision medicine. Its proprietary NGS-adapted chemistry and HTG EdgeSeq platform automates sample processing and can quickly, robustly, and simultaneously profile hundreds or thousands of molecular targets using a relatively small amount of biological samples, in liquid or solid forms. Its products include instruments, consumables, and software that combine to form its HTG EdgeSeq platform. The company's menu of HTG EdgeSeq molecular profiling panels is automated on its HTG EdgeSeq platform, applying genomic sequencing tools to quickly generate gene expression data using its simplified workflow for customers. |
| URL | https://www.htgmolecular.com |
| Investor Relations URL | http://investors.htgmolecular.com/phoenix.zhtml?c=253870&p=irol-irhome |
| HQ State/Province | Arizona |
| Sector | Health Care |
| Industry | Health Care Technology |
| Equity Style | Small Cap/Value |
| Next Earnings Release | Aug. 12, 2024 (est.) |
| Last Earnings Release | May. 11, 2023 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Ratings
Profile
| HTG Molecular Diagnostics Inc is a commercial-stage RNA platform-based life sciences company focused on advancing the promise of precision medicine. Its proprietary NGS-adapted chemistry and HTG EdgeSeq platform automates sample processing and can quickly, robustly, and simultaneously profile hundreds or thousands of molecular targets using a relatively small amount of biological samples, in liquid or solid forms. Its products include instruments, consumables, and software that combine to form its HTG EdgeSeq platform. The company's menu of HTG EdgeSeq molecular profiling panels is automated on its HTG EdgeSeq platform, applying genomic sequencing tools to quickly generate gene expression data using its simplified workflow for customers. |
| URL | https://www.htgmolecular.com |
| Investor Relations URL | http://investors.htgmolecular.com/phoenix.zhtml?c=253870&p=irol-irhome |
| HQ State/Province | Arizona |
| Sector | Health Care |
| Industry | Health Care Technology |
| Equity Style | Small Cap/Value |
| Next Earnings Release | Aug. 12, 2024 (est.) |
| Last Earnings Release | May. 11, 2023 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |